Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Queensland Health
McKesson
Daiichi Sankyo
Healthtrust
Chubb
Farmers Insurance
Moodys
Baxter
UBS

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,696,493

« Back to Dashboard

Which drugs does patent 6,696,493 protect, and when does it expire?

Patent 6,696,493 protects CARNITOR and is included in one NDA.

This patent has four patent family members in four countries.
Summary for Patent: 6,696,493
Title: Treating chronic uremic patients undergoing periodic dialysis
Abstract:The method for the treatment of chronic uremic patients undergoing periodical dialysis is useful for preventing and/or treating carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. The method according to the present invention comprises administering an effective dose of carnitine intravenously into the venous return line after each dialysis session.
Inventor(s): Cavazza; Claudio (Rome, IT)
Assignee: Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (Rome, IT)
Application Number:10/189,451
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,696,493

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Leadiant Biosci Inc CARNITOR levocarnitine INJECTABLE;INJECTION 020182-001 Dec 16, 1992 AP RX Yes Yes ➤ Subscribe ➤ Subscribe USE OF LEVOCARITINE IN PREVENTION AND TREATMENT OF CARNITINE DEFICIENCY IN PATIENTS WITH END STAGE RENAL DISEASE WHO ARE UNDERGOING DIALYSIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,696,493

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,335,369 Treating chronic uremic patients undergoing periodical dialysis ➤ Subscribe
6,429,230 Treating chronic uremic patients undergoing periodical dialysis ➤ Subscribe
6,914,076 Treating chronic uremic patients undergoing periodical dialysis ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,696,493

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 3050201 ➤ Subscribe
Canada 2381187 ➤ Subscribe
European Patent Office 1257266 ➤ Subscribe
World Intellectual Property Organization (WIPO) 0152836 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

US Army
QuintilesIMS
Cerilliant
Johnson and Johnson
UBS
Daiichi Sankyo
Argus Health
Express Scripts
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot